The evolution of mendelian randomization for investigating drug effects.
Dipender Gill and Stephen Burgess discuss the accompanying study by James Yarmolinsky and colleagues investigating the associations between genetically-proxied inhibition of antihypertensive drug targets and risk of common cancer subtypes using Mendelian randomization.
Saved in:
| Main Authors: | Dipender Gill, Stephen Burgess |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-02-01
|
| Series: | PLoS Medicine |
| Online Access: | https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1003898&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Angiotensin-converting enzyme inhibitors for aortic stenosis: a drug-target Mendelian randomization study
by: Jonathan L. Ciofani, et al.
Published: (2025-08-01) -
Associations of Genetically Predicted NPR3 and NPR2 Perturbation and Preeclampsia Risk: A Two-Sample Mendelian Randomization Analysis
by: Roxane de La Harpe, et al.
Published: (2025-01-01) -
Treatment of severe covid-19 with interleukin 6 receptor inhibition
by: Stephen Burgess, et al.
Published: (2022-12-01) -
Genetically proxied lean mass and risk of Alzheimer’s disease: mendelian randomisation study
by: Dipender Gill, et al.
Published: (2023-10-01) -
Proteome‐Wide Mendelian Randomization Identifies Natriuretic Peptide‐B and Novel Proteins as Potential Regulators of Pulse Pressure in Humans
by: Marie‐Joe Dib, et al.
Published: (2025-08-01)